AR043487A1 - Heterociclos fusionados de pirimidina y usos de los mismos - Google Patents
Heterociclos fusionados de pirimidina y usos de los mismosInfo
- Publication number
- AR043487A1 AR043487A1 ARP040100701A ARP040100701A AR043487A1 AR 043487 A1 AR043487 A1 AR 043487A1 AR P040100701 A ARP040100701 A AR P040100701A AR P040100701 A ARP040100701 A AR P040100701A AR 043487 A1 AR043487 A1 AR 043487A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- independently selected
- alkyl
- alkynyl
- alkenyl
- Prior art date
Links
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 6
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 5
- 125000004426 substituted alkynyl group Chemical group 0.000 abstract 5
- 125000003107 substituted aryl group Chemical group 0.000 abstract 5
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 5
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos, composiciones farmacéuticas que los contienen y métodos de uso de los mismos. Estos nuevos compuestos proveen un tratamiento o profilaxis del cáncer. Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula estructural (1) donde: A es C=O, CH2, o SO2; B representa alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, arilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, o heterociclo opcionalmente sustituido; D es O o N donde O es opcionalmente sustituido con un R8, donde N es opcionalmente sustituido con uno o más R8, y cuando n es 0 y m es 0, R8 se adjunta directamente a B; R1 y R2 en combinación forman un anillo heteroaromático fusionado de 5 miembros está opcionalmente sustituido con 1 o 2 sustituyentes, dicho anillo tiene al menos un átomo de N, O o S, pero no más de 2 átomos de O o 2 átomos de S o 1 átomo de O y un átomo de S; R3 se selecciona independientemente entre H, alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, cicloalquenilo opcionalmente sustituido, cicloalquinilo opcionalmente sustituido, arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido; R4 y R5 se seleccionan independientemente entre H o alquilo opcionalmente sustituido, o R4 y R5 en combinación forman un anillo de 3, 4, 5 o 6 miembros, el cual puede también ser opcionalmente sustituido; R6 y R7 se seleccionan independientemente entre H, alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, cicloalquenilo opcionalmente sustituido, cicloalquinilo opcionalmente sustituido, heterociclo opcionalmente sustituido, arilo opcionalmente sustituido, o R6 y R7 en combinación forman un anillo de 3,4, 5 o 6 miembros, el cual también puede ser sustituido; R8 se selecciona independientemente entre H, alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, cicloalquenilo opcionalmente sustituido, cicloalquinilo opcionalmente sustituido, arilo opcionalmente sustituido, o heterociclo opcionalmente sustituido; R9 se selecciona independientemente entre H, alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, cicloalquenilo opcionalmente sustituido, cicloalquinilo opcionalmente sustituido, arilo opcionalmente sustituido, o heterociclo opcionalmente sustituido.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0300627A SE0300627D0 (sv) | 2003-03-07 | 2003-03-07 | Novel fused heterocycles and uses therof |
| SE0301138A SE0301138D0 (sv) | 2003-04-15 | 2003-04-15 | Novel fused heterocycles and uses thereof |
| SE0301697A SE0301697D0 (sv) | 2003-06-10 | 2003-06-10 | Novel fused heterocycles and uses thereof |
| SE0302826A SE0302826D0 (sv) | 2003-10-24 | 2003-10-24 | Novel fused heterocycles and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR043487A1 true AR043487A1 (es) | 2005-08-03 |
Family
ID=32966643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040100701A AR043487A1 (es) | 2003-03-07 | 2004-03-05 | Heterociclos fusionados de pirimidina y usos de los mismos |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20060270689A1 (es) |
| EP (1) | EP1601673B1 (es) |
| JP (2) | JP3947758B2 (es) |
| KR (1) | KR20050107784A (es) |
| AR (1) | AR043487A1 (es) |
| AT (1) | ATE433448T1 (es) |
| AU (1) | AU2004218080B2 (es) |
| BR (1) | BRPI0408150A (es) |
| CA (1) | CA2518224C (es) |
| CY (1) | CY1109300T1 (es) |
| DE (1) | DE602004021477D1 (es) |
| DK (1) | DK1601673T3 (es) |
| ES (1) | ES2326647T3 (es) |
| IS (1) | IS8036A (es) |
| MX (1) | MXPA05009577A (es) |
| MY (1) | MY141583A (es) |
| NO (1) | NO20054340L (es) |
| NZ (1) | NZ542227A (es) |
| PL (1) | PL1601673T3 (es) |
| PT (1) | PT1601673E (es) |
| SI (1) | SI1601673T1 (es) |
| TW (1) | TW200510427A (es) |
| UA (1) | UA81470C2 (es) |
| WO (1) | WO2004078758A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7230000B1 (en) | 1999-10-27 | 2007-06-12 | Cytokinetics, Incorporated | Methods and compositions utilizing quinazolinones |
| US6545004B1 (en) | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| WO2003070701A2 (en) | 2002-02-15 | 2003-08-28 | Cytokinetics, Inc. | Syntheses of quinazolinones |
| KR20050036911A (ko) | 2002-05-09 | 2005-04-20 | 싸이토키네틱스, 인코포레이티드 | 화합물들, 방법 및 조성물 |
| WO2003097053A1 (en) | 2002-05-09 | 2003-11-27 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| WO2003103575A2 (en) | 2002-05-23 | 2003-12-18 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| JP2005538062A (ja) | 2002-06-14 | 2005-12-15 | サイトキネティクス・インコーポレーテッド | 化合物、組成物、および方法 |
| AU2003256805A1 (en) | 2002-07-23 | 2004-02-09 | Cytokinetics, Inc. | Compounds compositions and methods |
| AU2003277079A1 (en) | 2002-09-30 | 2004-05-04 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| WO2006018628A1 (en) * | 2003-03-07 | 2006-02-23 | Astrazeneca Ab | Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer |
| KR20050122220A (ko) * | 2003-03-25 | 2005-12-28 | 다케다 샌디에고, 인코포레이티드 | 디펩티딜 펩티다제 억제제 |
| US7022850B2 (en) | 2003-05-22 | 2006-04-04 | Bristol-Myers Squibb Co. | Bicyclicpyrimidones and their use to treat diseases |
| EP1692112A4 (en) | 2003-12-08 | 2008-09-24 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS, AND METHODS |
| MY141233A (en) * | 2004-08-18 | 2010-03-31 | Astrazeneca Ab | Enantiomers of selected fused heterocyclics and uses thereof |
| RU2007109867A (ru) * | 2004-08-18 | 2008-09-27 | Астразенека Аб (Se) | Выбранные конденсированные гетероциклы и их применение |
| WO2006078574A2 (en) * | 2005-01-19 | 2006-07-27 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| DE102005011822A1 (de) * | 2005-03-15 | 2006-09-21 | Merck Patent Gmbh | Phthalazinone |
| DE102005027168A1 (de) | 2005-06-13 | 2006-12-14 | Merck Patent Gmbh | Tetrahydrochinoline |
| EP2170340B1 (en) | 2007-06-21 | 2016-02-24 | Neuronascent, INC. | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones |
| WO2009001214A2 (en) * | 2007-06-28 | 2008-12-31 | Pfizer Products Inc. | Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists |
| CN114478429B (zh) * | 2020-11-13 | 2023-11-17 | 中国科学院大连化学物理研究所 | 一种3-烷硫基异噻唑衍生物及其合成方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6545004B1 (en) * | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| US7230000B1 (en) * | 1999-10-27 | 2007-06-12 | Cytokinetics, Incorporated | Methods and compositions utilizing quinazolinones |
| KR100883184B1 (ko) * | 2000-12-11 | 2009-02-12 | 암젠 인코포레이션 | Ｃｘｃｒ3 길항제 |
| US6809102B2 (en) * | 2001-03-29 | 2004-10-26 | Bristol-Myers Squibb Company | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| WO2003039460A2 (en) * | 2001-11-07 | 2003-05-15 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| WO2003043995A1 (en) * | 2001-11-20 | 2003-05-30 | Cytokinetics, Inc. | Process for the racemization of chiral quinazolinones |
| JP4467979B2 (ja) * | 2001-12-06 | 2010-05-26 | メルク・シャープ・エンド・ドーム・コーポレイション | 有糸分裂キネシン阻害剤 |
| DE60222302T2 (de) * | 2001-12-06 | 2008-05-29 | Merck & Co., Inc. | Inhibitoren von mitotischem kinesin |
| WO2003049527A2 (en) * | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| EP1465896A4 (en) * | 2001-12-06 | 2006-01-11 | Merck & Co Inc | INHIBITORS OF MITOTIC KINESINE |
| CA2468266A1 (en) * | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Substituted bicyclic pyrimidinones as a mitotic kinesin ksp inhibitors |
| KR101052816B1 (ko) * | 2002-04-17 | 2011-07-29 | 스미스 클라인 비참 코포레이션 | 화합물, 조성물 및 방법 |
| KR20050036911A (ko) * | 2002-05-09 | 2005-04-20 | 싸이토키네틱스, 인코포레이티드 | 화합물들, 방법 및 조성물 |
| WO2003097053A1 (en) * | 2002-05-09 | 2003-11-27 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| WO2003103575A2 (en) * | 2002-05-23 | 2003-12-18 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| JP2005533119A (ja) * | 2002-07-17 | 2005-11-04 | サイトキネティクス・インコーポレーテッド | 化合物、組成物、及び方法 |
| US7022850B2 (en) * | 2003-05-22 | 2006-04-04 | Bristol-Myers Squibb Co. | Bicyclicpyrimidones and their use to treat diseases |
| US7345046B2 (en) * | 2003-05-30 | 2008-03-18 | Chiron Corporation | Heteroaryl-fused pyrimidinyl compounds as anticancer agents |
| ATE458735T1 (de) * | 2003-06-20 | 2010-03-15 | Novartis Vaccines & Diagnostic | Pyridino[1,2-a pyrimidin-4-onverbindungen als mittel gegen krebs |
| US20050165089A1 (en) * | 2003-10-06 | 2005-07-28 | Gustave Bergnes | Compounds, compositions and methods |
| JP2007510660A (ja) * | 2003-11-07 | 2007-04-26 | サイトキネティクス・インコーポレーテッド | 化合物、組成物及び方法 |
| US20050158320A1 (en) * | 2003-11-12 | 2005-07-21 | Nichols M. J. | Combinations for the treatment of proliferative diseases |
| US7501416B2 (en) * | 2004-02-06 | 2009-03-10 | Bristol-Myers Squibb Company | Quinoxaline compounds and methods of using them |
| EP1732926B1 (en) * | 2004-04-06 | 2008-12-31 | Novartis Vaccines and Diagnostics, Inc. | Mitotic kinesin inhibitors |
| MX2007004699A (es) * | 2004-10-19 | 2007-06-14 | Novartis Vaccines & Diagnostic | Derivados de indol y bencimidazol. |
-
2004
- 2004-03-04 DE DE602004021477T patent/DE602004021477D1/de not_active Expired - Lifetime
- 2004-03-04 SI SI200431186T patent/SI1601673T1/sl unknown
- 2004-03-04 WO PCT/SE2004/000304 patent/WO2004078758A1/en not_active Ceased
- 2004-03-04 AU AU2004218080A patent/AU2004218080B2/en not_active Ceased
- 2004-03-04 DK DK04717339T patent/DK1601673T3/da active
- 2004-03-04 BR BRPI0408150-1A patent/BRPI0408150A/pt not_active IP Right Cessation
- 2004-03-04 MX MXPA05009577A patent/MXPA05009577A/es active IP Right Grant
- 2004-03-04 EP EP04717339A patent/EP1601673B1/en not_active Expired - Lifetime
- 2004-03-04 JP JP2006507939A patent/JP3947758B2/ja not_active Expired - Fee Related
- 2004-03-04 ES ES04717339T patent/ES2326647T3/es not_active Expired - Lifetime
- 2004-03-04 AT AT04717339T patent/ATE433448T1/de active
- 2004-03-04 PL PL04717339T patent/PL1601673T3/pl unknown
- 2004-03-04 CA CA2518224A patent/CA2518224C/en not_active Expired - Fee Related
- 2004-03-04 MY MYPI20040755A patent/MY141583A/en unknown
- 2004-03-04 NZ NZ542227A patent/NZ542227A/en not_active IP Right Cessation
- 2004-03-04 KR KR1020057016722A patent/KR20050107784A/ko not_active Ceased
- 2004-03-04 PT PT04717339T patent/PT1601673E/pt unknown
- 2004-03-04 US US10/548,138 patent/US20060270689A1/en not_active Abandoned
- 2004-03-05 AR ARP040100701A patent/AR043487A1/es not_active Application Discontinuation
- 2004-03-05 TW TW093105906A patent/TW200510427A/zh unknown
- 2004-04-03 UA UAA200509430A patent/UA81470C2/uk unknown
-
2005
- 2005-09-19 IS IS8036A patent/IS8036A/is unknown
- 2005-09-20 NO NO20054340A patent/NO20054340L/no unknown
-
2006
- 2006-07-25 JP JP2006201461A patent/JP2007063257A/ja active Pending
-
2009
- 2009-08-10 CY CY20091100845T patent/CY1109300T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20054340L (no) | 2005-09-26 |
| ATE433448T1 (de) | 2009-06-15 |
| AU2004218080B2 (en) | 2008-01-03 |
| HK1084390A1 (en) | 2006-07-28 |
| DK1601673T3 (da) | 2009-08-24 |
| UA81470C2 (en) | 2008-01-10 |
| MXPA05009577A (es) | 2005-12-12 |
| KR20050107784A (ko) | 2005-11-15 |
| CY1109300T1 (el) | 2014-07-02 |
| ES2326647T3 (es) | 2009-10-16 |
| CA2518224A1 (en) | 2004-09-16 |
| PT1601673E (pt) | 2009-07-29 |
| MY141583A (en) | 2010-05-14 |
| DE602004021477D1 (de) | 2009-07-23 |
| PL1601673T3 (pl) | 2009-10-30 |
| CA2518224C (en) | 2010-06-15 |
| SI1601673T1 (sl) | 2009-10-31 |
| BRPI0408150A (pt) | 2006-03-21 |
| JP2006519853A (ja) | 2006-08-31 |
| US20060270689A1 (en) | 2006-11-30 |
| NZ542227A (en) | 2008-12-24 |
| JP3947758B2 (ja) | 2007-07-25 |
| TW200510427A (en) | 2005-03-16 |
| JP2007063257A (ja) | 2007-03-15 |
| EP1601673A1 (en) | 2005-12-07 |
| AU2004218080A1 (en) | 2004-09-16 |
| WO2004078758A1 (en) | 2004-09-16 |
| IS8036A (is) | 2005-09-19 |
| EP1601673B1 (en) | 2009-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR043487A1 (es) | Heterociclos fusionados de pirimidina y usos de los mismos | |
| PE20220567A1 (es) | Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| PE20190326A1 (es) | Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas | |
| AR088449A1 (es) | Benzilindazoles sustituidos | |
| PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
| ECSP034865A (es) | Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas | |
| YU48390B (sh) | Novi derivati 2-anilinopirimidina, postupak za njihovo dobijanje i sredstva za uništavanje štetočina, koja sadrže ove derivate | |
| AR020165A1 (es) | Derivados de pirimidinas sustituidas, su procedimiento de preparacion, composiciones farmaceuticas que las contienen y el uso de los mismos para la preparacion de medicamentos | |
| AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
| AR038536A1 (es) | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados | |
| AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
| PE20080524A1 (es) | DERIVADOS DE 1H-IMIDAZO[4,5-b]PIRAZIN Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN | |
| AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
| AR040773A1 (es) | Pirazoles utiles como inhibidores de gsk-3 | |
| CO5590895A2 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos | |
| ECSP045369A (es) | Derivados de n-[fenil(piperidin-2-il)metil]benzamida, su preparacion y su aplicacion en terapeutica | |
| AR041395A1 (es) | Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla | |
| NO20050418L (no) | Kondenserte pyridiner og pyrimidiner med TIE2(TEK) aktivitet | |
| AR095708A1 (es) | Indazoles sustituidos con diaminoheteroarilo | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| CO5631434A2 (es) | Derivados de piridina-carboxamida y su uso como plaguicidas | |
| AR069814A1 (es) | Derivados de 4 amino-pirimidina, proceso de preparacion y composiciones farmaceuticas que los contienen | |
| AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
| AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure | ||
| FA | Abandonment or withdrawal | ||
| FB | Suspension of granting procedure |